Signet Therapeutics Announces Co-Founder Dr. Adam Bass to Deepen Involvement in Financing, Pipeline Strategy, and Global Collaborations to Accelerate Innovative Drug Development

Recently, Signet Therapeutics (hereinafter referred to as "Signet") announced that the company's co-founder and global authority in gastric cancer researchProfessor Adam Bass will be deeply involved in the company's financing, pipeline strategic layout, business development, and global cooperation., further advancing the research and commercialization process of SIGNET's innovative drugsProfessor Adam Bass is planning to visit China this May for a two-week exchange to promote international cooperation and innovation in the biopharmaceutical field.

Professor Adam Bass isInternational authoritative expert in the field of gastric cancer and esophageal cancer research, once served asChair of The Cancer Genome Atlas (TCGA) Gastric Cancer and Esophageal Cancer Project, achieving several breakthrough results in the field of cancer genomics and translational medicine. As the corresponding author, he has published inNature，Cancer Cell，Cancer DiscoveryAndNature GeneticsPublished in top-tier academic journalsImpact Factor 20+'s Thesis20More than...His research has laid an important foundation for the molecular subtyping and targeted therapy of gastric cancer., which has had a profound impact on the progress of global gastric cancer treatment. Professor Adam Bass is not only a co-founder of Signet Therapeutics but also served as a professor at the Dana-Farber Cancer Institute of Harvard University and in the Oncology Translational Research department at Novartis.)Global Leader, Directed the Development and Translation of Multiple Innovative Drugs.

As the co-founder of SIGNET, Professor Adam Bass will leverage his extensive experience in cancer research and drug development to deeply participate in the company's financing and global business expansion. He will introduce more strategic resources and partners to SIGNET, accelerating the company's globalization process.

SIGNET is a global pioneer in the "organoid + AI" drug development model, recognized as a specialized and innovative enterprise in Shenzhen and certified as a National High-tech Enterprise. The company originated on the campus of Harvard University and officially established its presence in Shenzhen by the end of 2020, having since secured nearly 220 million yuan in funding and project grants. Currently, the company has four drug pipelines, with the first pipeline developing SIGX1094, the world’s first targeted drug for diffuse gastric cancer. It has obtained IND approval from both the U.S. FDA and China’s NMPA, and received Orphan Drug Designation and Fast Track Designation from the U.S. FDA. The drug has now entered Phase I clinical trials.

Signet is not only the phonetic translation of "Signet" but also adheres to the vision of "Full of Hope, Studying Things to Gain Knowledge." The company leverages the critical role of organoid disease models that closely resemble patients' genomic characteristics in drug efficacy evaluation and new target discovery. By integrating AI-powered screening, synthesis, and optimization of small-molecule compounds, Signet develops first-in-class innovative targeted drugs. The company has a 1200㎡ R&D facility and a 500㎡ experimental animal housing area. SIGNET's organoid platform not only serves its own drug pipeline but also actively empowers large pharmaceutical companies in new drug development. Collaborative partners include Shenzhen Second People's Hospital, the University of Hong Kong, the Hong Kong University of Science and Technology, Shenzhen BioRay Pharma, and Genuine Biotech, contributing to the creation of more innovative drugs.